BioCardia, Inc. raised $4.4 million by selling 3.5 million shares at $1.279 each to extend its cash runway into early 2027, supporting its upcoming Japan PMDA submission for CardiAMP cell therapy. The company expects that if outstanding warrants are exercised, it could maintain funding well beyond regulatory approval and into commercial sales. This financing supports BioCardia's development of cellular therapies for cardiovascular diseases, with key milestones including a Japan PMDA submission expected in late 2026. The funds help advance their clinical programs and prepare for market entry.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
Gooch & Housego, a UK-listed photonics company specializing in precision optics for aerospace and defence, has agreed to a £345.6 million takeover by US private equity firm Arlington Capital Partners. The offer values the company at a 41.3% premium t...
Aave DAO has proposed an innovative mobile app that integrates fiat currency deposits, self-custody, and decentralized finance (DeFi) lending in one platform. This app allows users to convert fiat to stablecoins and earn yields without needing extern...
Analysts expect Netflix to report $12.6 billion in revenue for Q2 and $51.3 billion for the full year 2026. The operating margin forecast has been revised down from 33% to 32% due to anticipated higher expenses, with an expected operating profit of $...
